Pediatr Infect Dis J 2021 Jul 20. Epub 2021 Jul 20.
From the Paediatric Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom; Department of Pathology, University of Otago, Christchurch, New Zealand; NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom; International Vaccine Access Centre, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; and Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London, London, United Kingdom.
Background: The pneumococcal conjugate vaccine has had a substantial impact on invasive pneumococcal disease. Previously, we compared immunity following vaccination with the 10-valent pneumococcal conjugate vaccine (PCV10) administered at 2 slightly different schedules: at 6 and 10 weeks of age, and at 6 and 14 weeks of age, both followed by a 9-month booster. In this study, we followed up those participants to evaluate the medium-term persistence of serotype-specific pneumococcal immunity at 2-3 years of age. Read More